By: Benzinga
UPDATE: Dawson James Initiates Affymax at Market Outperform on Momentum
Dawson James initiated coverage on Affymax (NASDAQ: AFFY ) with a Market Outperform rating and a $32 price target. Dawson James commented, "Commercialization of new products is always tricky, especially in the current environment; however, we believe Omontys is an ideal product for the dialysis market given the new
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here